Navigation Links
Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
Date:5/9/2013

NANJING, China, May 9, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended March 31, 2013.

Highlights

  • Total revenue was RMB528.7 million (US$85.1 million) for the first quarter of 2013, compared to RMB487.6 million for the same period in 2012, representing an increase of 8.4%.
  • Gross margin for the first quarter of 2013 was 79.2%, compared to 82.0% for the same period in 2012.
  • Income from operations was RMB50.2 million (US$8.1 million) for the first quarter of 2013, compared to RMB43.3 million for the same period in 2012, representing an increase of 16.0%.
  • Net income attributable to Simcere was RMB29.9 million (US$4.8 million) for the first quarter of 2013, an increase of 4.6% from RMB28.6 million for the same period in 2012.
  • Mr. Hongquan Liu, Executive Director and Chief Executive Officer of Simcere Pharmaceutical Group, commented, "We experienced moderate sales growth in the first quarter despite sustained pricing restrictions from the government and intensifying competition. I am pleased that our overall business performance improved during the quarter and that both Sales and Marketing expenses and General and Administrative expenses as percentages of our total revenue decreased slightly."

    On March 11, 2013, the Company announced that it received a "going private" proposal. Simcere's Board of Directors has formed a special committee to consider the proposed transaction.

    2013 First Quarter Financial Results Total revenue for the first quarter of 2013 was RMB528.7 million (US$85.1 million), compared to RMB487.6 million for the same period in 2012, representing an increase of 8.4%.

    The table below sets forth the Company's top 10 products by revenue for the three months ended March 31, 2013:In ThousandsThree months ended  March 31, 2013

    Three months ended March 31, 2012RMBUSD% of total 
    revenueRMB% of total 
    revenueChangeProductsTherapeutic Area  Edaravone

    Neuroscience

    144,256

    23,227

    27.3%

    160,902

    33.0%

    (10.3%)Endu

    Oncology

    80,228

    12,917

    15.2%

    56,350

    11.6%

    42.4%Zailin 

    Infectious Disease

    62,569

    10,074

    11.8%

    60,033

    12.3%

    4.2%Yintaiqing

    Inflammation

    48,456

    7,802

    9.2%

    33,147

    6.8%

    46.2%Sinofuan

    Oncology

    32,644

    5,256

    6.2%

    39,290

    8.1%

    (16.9%)Biqi 

    Gastroenterology

    24,419

    3,932

    4.6%

    21,908

    4.5%

    11.5%Kechuanning

    Respiratory

    17,524

    2,822

    3.3%

    13,870

    2.8%

    26.3%Jiebaishu

    Oncology

    17,153

    2,762

    3.2%

    15,227

    3.1%

    12.6%Anxin

    Infectious Disease

    16,626

    2,677

    3.1%

    15,514

    3.2%

    7.2%Anqi 

    Infectious Disease

    13,673

    2,201

    2.6%

    15,773

    3.2%

    (13.3%)Others71,181

    11,461

    13.5%

    55,595

    11.4%

    28.0%Total 528,729

    85,131

    100.0%

    487,609

    100.0%

    8.4%For more information about the above products, please visit our corporate website: www.simcere.comGross margin for the first quarter of 2013 was 79.2%, compared to 82.0% for the same period in 2012. The decrease was primarily due to the percentage decrease in sales of drugs with higher gross margins and certain fixed overhead costs incurred before the commercial production of influenza vaccine products.

    Research and development expenses for the first quarter of 2013 totaled RMB44.9 million (US$7.2 million), which represented a decrease of 7.0% from RMB48.3 million for the same period in 2012. The decrease was primarily due to the completion of development of the Company's influenza vaccine product and its transition to commercial manufacturing. As a percentage of total revenue, research and development expenses decreased to 8.5% for the first quarter of 2013 from 9.9% for the same period in 2012.

    Sales, marketing and distribution expenses for the first quarter of 2013 were RMB259.6 million (US$41.8 million), which represented an increase of 0.3% from RMB258.8 million for the same period in 2012. As a percentage of total revenue, sales, marketing and distribution expenses decreased to 49.1% for the first quarter of 2013 from 53.1% for the same period in 2012.

    General and administrative expenses were RMB64.0 million (US$10.3 million) for the first quarter of 2013, which represented a decrease of 1.6% from RMB65.1 million for the same period in 2012. As a percentage of total revenue, general and administrative expenses decreased to 12.1% for the first quarter of 2013 from 13.3% for the same period in 2012.

    Share-based compensation expenses, which were allocated to research and development expenses, sales, marketing and distribution expenses, and general and administrative expenses, based on the nature of the work that the relevant employee was assigned to perform, totaled RMB9.8 million (US$1.6 million) for the first quarter of 2013. Share-based compensation expenses for the first quarter of 2012 were RMB3.8 million. The increase was primarily due to restricted shares granted to our management in the second half of 2012.

    Income from operations was RMB50.2 million (US$8.1 million) for the first quarter of 2013, representing an increase of 16.0% from RMB43.3 million for the same period in 2012.

    Income tax expense for the first quarter of 2013 was RMB6.5 million (US$1.0 million), compared to income tax expense of RMB2.6 million for the same period in 2012. The effective income tax rate increased to 23.9% in the first quarter of 2013 from 10.4% for the same period in 2012. The lower effective income tax rate in the first quarter of 2012 was primarily due to the impact of other operating income of RMB15.6 million in the first quarter of 2012 recorded by our subsidiary located in the British Virgin Islands which is not subject to income tax.

    Net income attributable to Simcere was RMB29.9 million (US$4.8 million) for the first quarter of 2013, compared to RMB28.6 million for the same period in 2012. Net margin, representing net income attributable to Simcere divided by total revenue, was 5.7% for the first quarter of 2013, compared to 5.9% for the same period in 2012.

    Basic and diluted earnings per American Depository Share ("ADS") for the first quarter of 2013 were RMB0.57 (US$0.09) and RMB0.56 (US$0.09), respectively. One ADS represents two ordinary shares of the Company.

    As of March 31, 2013, the Company had cash and pledged bank deposits of RMB332.9 million (US$53.6 million), compared to RMB201.6 million as of December 31, 2012.

    Financial InformationThe preliminary unaudited condensed consolidated statements of income and balance sheets accompanying this press release have been prepared by management using U.S. GAAP. This preliminary financial information is not intended to fully comply with U.S. GAAP because it does not present all of the financial information and disclosures required by U.S. GAAP.

    Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, the quotations from management in this press release contain forward-looking statements. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    Conference CallSimcere Pharmaceutical Group will host a conference call to discuss the Company's results for the first quarter of 2013 on Thursday, May 9, at 8:00 a.m. Eastern Time (Thursday, May 9 at 8:00 p.m. Beijing/Hong Kong time). The management team will be on the call to discuss the results for the first quarter of 2013 and to answer questions.

    To access the conference call, please dial:International toll:

    +65.6723.9381United States toll-free:

    +1.866.519.4004United States toll:

    +1.718.354.1231China Domestic toll:

    800.819.0121 China Domestic mobile toll:

    400.620.8038 Hong Kong toll:

    +852.2475.0994Please ask to be connected to Q1 2013 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 58031483.

    Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

    Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:

    +1. 855.452.5696United States toll:

    +1. 646.254.3697The passcode for replay participants is 58031483. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

    About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.comIn Nanjing: In the United States:Jie Liu D'Elia 

    Cindy ZhengVice President

    Brunswick GroupSimcere Pharmaceutical Group 

    Tel: 1-212-333-3810Tel: 86-25-8556-6666*8857 In Beijing:Yue YuBrunswick Group Tel: 86-10-5960-8600 SIMCERE PHARMACEUTICAL GROUPPRELIMINARY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (AMOUNTS EXPRESSED IN THOUSANDS, EXCEPT SHARE AND ADS DATA)

    Three months ended March 31,

    201220132013RMBRMBUSDProduct revenue

    487,609

    528,729

    85,131Total revenue487,609528,72985,131Cost of materials and production

    (87,838)

    (110,047)

    (17,719)Gross profit399,771418,68267,412Operating expenses and other operating income:Research and development

    (48,286)

    (44,930)

    (7,234)Sales, marketing and distribution

    (258,792)

    (259,557)

    (41,791)General and administrative

    (65,082)

    (64,012)

    (10,307)Other operating income

    15,650

    -

    -Income from operations

    43,261

    50,183

    8,080Interest income

    861

    868

    140Interest expense

    (20,193)

    (13,101)

    (2,109)Foreign currency exchange gains (losses)

    (57)

    (26)

    (4)Other  income

    4,081

    1,190

    191Losses of equity method affiliated

    company

    (2,543)

    (11,853)

    (1,909)Earnings  before income taxes  25,41027,2614,389Income tax expense

    (2,637)

    (6,506)

    (1,047)Net Income22,77320,7553,342Less: Net loss attributable to the
    non-controlling interest

    5,851

    9,188

    1,479Net income attributable to Simcere28,624

    29,943

    4,821Earnings  per share attributable to Simcere:Basic

    0.26

    0.28

    0.05Diluted

    0.26

    0.28

    0.05Earnings  per ADS attributable to Simcere:Basic

    0.53

    0.57

    0.09Diluted

    0.53

    0.56

    0.09Weighted average number of common shares: Basic

    108,438,176

    105,157,800

    105,157,800Diluted

    108,703,148

    106,128,250

    106,128,250 SIMCERE PHARMACEUTICAL GROUPPRELIMINARY UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (AMOUNTS EXPRESSED IN THOUSANDS)December 31,March 31,March 31,2012RMB2013RMB2013USDAssetsCurrent assetsCash and pledged bank deposits

    201,556

    332,917

    53,603Assets held for sale

    90,550

    90,550

    14,580Bills receivable

    679,630

    614,257

    98,901Accounts receivable, net

    413,481

    419,796

    67,591Inventories

    120,932

    97,521

    15,702Other current assets

    237,248

    221,442

    35,654Total current assets1,743,3971,776,483286,031Property, plant and equipment, net

    853,546

    848,367

    136,596Land use rights

    128,220

    127,466

    20,523Goodwill and intangible assets, net

    519,334

    512,119

    82,456Investments in and advances to affiliated companies

    56,785

    41,487

    6,680Other non-current assets

    71,381

    96,304

    15,506Total assets3,372,663

    3,402,226

    547,792LiabilitiesCurrent liabilitiesShort-term borrowings

    675,779

    735,770

    118,466Accounts payable

    47,136

    35,371

    5,695Bills payable

    15,000

    -

    -Other payables and accrued liabilities

    471,603

    444,518

    71,572Total current liabilities1,209,5181,215,659195,733Long-term borrowings

    2,000

    2,000

    322Deferred tax liabilities

    56,120

    50,072

    8,062Other liabilities

    32,657

    31,657

    5,097Total liabilities1,300,2951,299,388209,214Shareholders' equitySimcere shareholders' equity Ordinary shares at par

    8,258

    8,259

    1,330Additional paid-in capital

    853,551

    863,329

    139,004Accumulated other comprehensive loss

    (104,147)

    (104,211)

    (16,779)Retained earnings

    1,254,464

    1,284,407

    206,802Total equity attributable to Simcere2,012,1262,051,784330,357Non-controlling interest60,24251,0548,221Total shareholders' equity2,072,3682,102,838338,578Commitments and contingenciesTotal liabilities and shareholders' equity3,372,663

    3,402,226

    547,792Note: The conversions of Renminbi (RMB) into United States dollars (USD) as at the reporting dates are based on the noon buying rate of USD1.00 = RMB6.2108 on March 31, 2013 as set forth in the H.10 statistical release of the Federal Reserve Board. No representation is intended to imply that the RMB amounts could have been, or could be, converted, realized or settled into U.S. dollars at that rate on the reporting dates.


    '/>"/>
    SOURCE Simcere Pharmaceutical Group
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
    2. Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
    3. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
    4. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
    5. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Legal Counsel
    6. Simcere Pharmaceutical Group Announces Receipt of "Going Private" Proposal
    7. Simcere Pharmaceutical Group Reports Preliminary Unaudited Fourth Quarter And Full Year 2012 Results
    8. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013
    9. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
    10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
    11. Simcere Pharmaceutical Group to Announce Third Quarter 2012 Financial Results on Thursday, November 15, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2016)... May 24, 2016   ... beide primären Endpunkte und demonstriert Ebenbürtigkeit ... ‚ausgezeichneter plus guter , ... ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... neue positive Daten von der MORA-Studie der Phase ...
    (Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
    (Date:5/24/2016)... , May 24, 2016 ... Education in Clinical Neurophysiology  Elsevier , ... products and services, today announced the launch of ... open access journal that focuses on clinical practice issues ... case reports, clinical series, normal values and didactic reviews. ...
    Breaking Medicine Technology:
    (Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the ... and suppliers for its inaugural Member Conference at the Paris Hotel in Las ... the operational health of America’s healthcare providers. , The conference was highlighted by ...
    (Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... The ... Project offering a new model of care for living and healing, celebrated its ... values: Meaningful Life in a Real Home provided by Empowered Staff. , “This is ...
    (Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... technologies and development solutions for drugs, biologics, consumer health and global clinical supply ... office in Korea to support the company’s continued investment and strategic growth plans ...
    (Date:5/26/2016)... , ... May 26, 2016 , ... Memorial Day Weekend ... Amica Insurance is sharing tips to make sure your family and vehicle ... the National Safety Council, there may be 439 deaths and an additional 50,500 serious ...
    (Date:5/26/2016)... ... May 26, 2016 , ... North Cypress Medical Center hosted ... Club in Cypress. With the help of community partners, the event organizers raised $45,000 ... hope for wounded service members and their families through health, wellness, and therapeutic support. ...
    Breaking Medicine News(10 mins):